Tassie Jean-Michel, Grabar Sophie, Lancar Rémi, Deloumeaux Jacqueline, Bentata Michèle, Costagliola Dominique
Institut National de la Santé et de la Recherche Médicale SC4, Faculté de Médecine, St. Antoine Université Pierre et Marie Curie, Paris, France; Epicentre, Paris, France.
J Acquir Immune Defic Syndr. 2002 May 1;30(1):81-7. doi: 10.1097/00042560-200205010-00011.
To estimate the change in AIDS incubation time during three periods characterized by different availability of antiretroviral treatments, data from the French Hospital Database on HIV of 4702 HIV-1-positive subjects with a documented date of infection were analyzed. Times from seroconversion to AIDS were compared in three periods: period 1 from January 1992 to June 1995 (monotherapy); period 2 from July 1995 to June 1996 (dual therapy); and period 3 from July 1996 to June 1999 (triple therapy). Nonparametric survival analyses were performed to account for staggered entries in the database and during each period. From periods 1 to 3, antiretroviral treatments were initiated earlier after infection, more subjects were treated, and the nature of regimens changed (25.6% of subjects were treated with monotherapy in period 1, 34.6% were treated with dual therapy in period 2, and 53.4% were treated with triple therapy in period 3). Compared with period 1, the relative hazard (RH) of AIDS was 0.31 in period 3 (95% confidence interval [CI]: 0.24-0.39). When comparing period 3 with period 2, the RH of AIDS was 0.36 (CI: 0.29-0.45). Assuming a log normal distribution, the median time to AIDS was estimated as 8.0 years in period 1 (CI: 6.0-10.6), 9.8 years in period 2 (CI: 8.5, 11.2), and 20.0 years in period 3 (CI: 17.1-23.3). This lengthening in time to AIDS from 1992 to 1999 was particularly marked in the period after the introduction of triple therapy, including protease inhibitors.
为评估在以抗逆转录病毒治疗可及性不同为特征的三个时期内艾滋病潜伏期的变化,我们分析了法国医院HIV数据库中4702名有记录感染日期的HIV-1阳性受试者的数据。比较了三个时期从血清转化到艾滋病的时间:1992年1月至1995年6月(单一疗法);1995年7月至1996年6月(联合疗法);以及1996年7月至1999年6月(三联疗法)。进行非参数生存分析以考虑数据库以及每个时期内的交错录入情况。从第1阶段到第3阶段,感染后开始抗逆转录病毒治疗的时间更早,接受治疗的受试者更多,治疗方案的性质也发生了变化(第1阶段25.6%的受试者接受单一疗法,第2阶段34.6%接受联合疗法,第3阶段53.4%接受三联疗法)。与第1阶段相比,第3阶段艾滋病的相对风险(RH)为0.31(95%置信区间[CI]:0.24 - 0.39)。将第3阶段与第2阶段比较时,艾滋病的RH为0.36(CI:0.29 - 0.45)。假设呈对数正态分布,第1阶段艾滋病的中位时间估计为8.0年(CI:6.0 - 10.6),第2阶段为9.8年(CI:8.5,11.2),第3阶段为20.0年(CI:17.1 - 23.3)。从1992年到1999年艾滋病发病时间的延长在引入包括蛋白酶抑制剂在内的三联疗法后的时期尤为明显。